Funding rounds in the canton of Basel-Stadt

20 rounds by startups based in the canton of Basel-Stadt, about CHF 484.2 M announced in total, from newest to oldest. The canton's public funding is on the Basel-Stadt grants page.

October 2026

  • Atlas Bio

    Atlas Bio uses AI to simulate clinical trials and drug behaviour, in order to replace part of phase II trials and animal testing.

    Seed · Basel · Biotech & life sciences · Creandum

    USD 10 M
  • Nouscom

    Nouscom is developing NOUS-209, a neoantigen-based immunotherapy designed to prevent cancers in carriers of Lynch syndrome.

    Series C and later · Basel · Biotech & life sciences · M Ventures, Revelation Partners, Angelini Industries and 12 more

    USD 135 M

August 2026

  • Indivi

    Indivi develops smartphone-based assessments of motor and cognitive function to detect treatment effects earlier in neurology clinical trials.

    Undisclosed round · Basel · Health & medtech · Infosys Innovation Fund

    Amount not disclosed
  • Vaderis Therapeutics

    Vaderis Therapeutics develops targeted therapies for rare vascular diseases, including engasertib for hereditary haemorrhagic telangiectasia.

    Series B · Basel · Biotech & life sciences · Goldman Sachs Alternatives, TCGX, Omega Funds and 5 more

    USD 152 M

June 2026

  • ClearideBio Therapeutics

    ClearideBio Therapeutics, founded in December 2025, develops antibody-drug conjugates against solid tumours.

    Pre-seed · Basel · Biotech & life sciences · LOTTE HOLDINGDS Healthcare & Biopharmaceutical CVC

    Amount not disclosed

May 2026

  • NUCLIDIUM

    NUCLIDIUM develops copper-based radiotheranostics for cancer diagnosis and treatment.

    Series B · Basel · Biotech & life sciences · Kurma Growth Opportunities Fund, Angelini Ventures, Aurea and 6 more

    CHF 26 M
  • upVolt

    upVolt extends the life of used lithium-ion batteries, turning them into second-life home batteries.

    Grant · Basel · Cleantech & climate · Klimastiftung Schweiz

    Amount not disclosed
  • Windward Bio

    Windward Bio develops antibodies against immunological diseases, including WIN378, an anti-TSLP in phase 2/3 testing in asthma.

    Undisclosed round · Basel · Biotech & life sciences · OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities and 10 more

    USD 165 M
  • BioCopy

    BioCopy develops TCR-mimetic bispecific antibodies against cancer, with an R&D site in Emmendingen, Germany.

    Series A · Basel · Biotech & life sciences

    CHF 9 M

April 2026

March 2026

February 2026

  • Axmed

    Axmed runs a B2B platform for procuring and distributing essential medicines in low- and middle-income countries.

    Grant · Basel · Health & medtech, Impact · Gates Foundation

    USD 6 M

January 2026

  • TECregen

    Founded in 2023, TECregen develops biologics aimed at regenerating the thymus to restore immune function.

    Seed · Basel · Biotech & life sciences · Boehringer Ingelheim Venture Fund (BIVF), LifeSpan Vision Ventures, Carma Fund and 4 more

    CHF 10 M

December 2025

November 2025

  • Indivi

    Indivi develops digital biomarkers that turn smartphones and everyday devices into measurement tools for neuroscience drug development.

    Undisclosed round · Basel · Health & medtech · Ava Investors, Leclercq American Capital

    CHF 15 M